Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome |
| |
| Authors: | Yuji Shimura Junya Kuroda Nana Sasaki Hitoji Uchiyama Muneo Ohshiro Yayoi Matsumura Hisao Nagoshi Shinsuke Mizutani Tsutomu Kobayashi Yosuke Matsumoto Shigeo Horiike Masafumi Taniwaki |
| |
| Institution: | aDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan;bDivision of Hematology, Department of Medicine, Kyoto Second Red Cross Hospital, Kyoto, Japan;cDivision of Hematology, Department of Medicine, Kyoto First Red Cross Hospital, Kyoto, Japan;dDepartment of Hematology, Matsushita Memorial Hospital, Osaka, Japan |
| |
| Abstract: | A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence of therapy-related myelodysplastic syndrome (t-MDS) in February 2012. In March 2012, we performed related allogeneic HSCT for the treatment of both malignancies. This strategy was successful and the patient has remained free from both malignancies for 23 months. Allogeneic HSCT is a potent curative therapeutic option for both t-MDS and refractory follicular lymphoma.Key words: Therapy-related myelodysplastic syndrome, Follicular lymphoma, Allogeneic transplantation |
| |
| Keywords: | |
|
|
